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Abstract
Optic neuropathy is damage to the optic nerve from any cause. Damage and death of 
these nerve cells lead to characteristic features of optic neuropathy. The main symptom 
is loss of vision (visual acuity and visual field damages), with colors appearing subtly 
washed out in the affected eye. The diagnosis is made on clinical examination. The history 
often points to the possible etiology of the optic neuropathy. In most of the cases, one eye 
is affected but it could be both. A rapid onset is typical of demyelinating, inflammatory, 
ischemic, and traumatic causes. A gradual course points to compressive, toxic/nutritional, 
and hereditary causes. The classic clinical signs of optic neuropathy are visual acuity and 
field defects, dyschromatopsia, and abnormal pupillary response. There are ancillary 
investigations that can support the diagnosis of optic neuropathy. Visual field testing, 
neuroimaging of the brain and orbit are essential in many optic neuropathies including 
demyelinating and compressive. In the last decade, increase of use new technology for 
optic neuropathies evaluation including multifocal visual evoked potentials and optic 
coherence tomography. Long standing of optic neuropathy is described by pale optic disk 
or optic atrophy, which means damage and death of these nerve cells or neurons.
Keywords: optic neuropathy, optic neuritis, non-arteritic anterior ischemic optic 
neuropathy (NAION), arteritic anterior ischemic optic neuropathy (AION), traumatic 
optic neuropathy
1. Introduction
Accurate medical history is very important information, helping to evaluate the etiology of 
visual loss. Rapid onset is characteristic of optic neuritis, ischemic optic neuropathy, inflam-
matory (non-demyelinating), and traumatic optic neuropathy. On the other hand, gradual 
onset over months or even years is typical of compressive toxic/nutritional optic neuropa-
thy. A history over years is seen in compressive and hereditary optic neuropathies. The 
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ophthalmologist or neurologist can make the differential diagnosis according the symptoms, 
the age of onset, and the gender. Young age group (15–45 years) for optic neuritis women 
gender and pain on eye movement are more typical for optic neuritis versus. Elderly patients 
(older than 50 years), painless loss of vision without gender predisposition are typical for isch-
emic optic neuropathy. Additionally, in a young patient, history of neurological symptoms 
such as parenthesis, limb weakness, and ataxia is suggestive of demyelinating optic neuritis.
In an elderly patient (more than 60 years mostly 70–80 years) with signs of severe optic 
neuropathy and the presence of preceding transient visual loss, temporal pain, jaw claudica-
tion, fatigue, fever, anemia, weight loss and myalgia, an arteritic ischemic optic neuropathy 
(AION) due to giant cell arteritis (GCA) should be suspected.
In children, a history of recent flu-like illness or vaccination days or weeks before vision loss 
points to a para-infectious or postvaccinia optic neuritis, respectively.
Transient visual obscurations, transient diplopia, and headache should raise the suspicion of 
increased intra-cranial pressure.
The use of any medications should be carefully noted, since some are either directly or 
indirectly toxic to the optic nerve. These include drugs as ethambutol, methanol, isoniazid, 
tobacco alcohol, and more. History of diabetes mellitus, systemic hypertension, hypercho-
lesterolemia, coagulation deficit, and smoking is more common in patients with nonarteritic 
ischemic optic neuropathy (NAION). Patients who have history of malignancy may have 
infiltrative or para-neoplastic optic neuropathy. It is important to inquire into the patient’s 
general health, eating, and social habits (drinking and smoking) in suspected nutritional optic 
neuropathy (complex B–vitamins). In addition, a detailed family history is inquired in diag-
nosing hereditary autosomal and mitochondrial optic neuropathies.
This chapter addresses the major diseases neuropathies accompanied by rapid visual loss: 
nonarteritic and arteritic optic neuropathy, traumatic optic neuropathy, and optic neuritis.
2. Anterior ischemic optic neuropathy (AION)
Anterior ischemic optic neuropathy (AION) is a medical condition involving insufficient 
blood supply of the pial vessels originating from the choroidal vessels to the optic disk. 
AION is generally divided into two types: arteritic AION (or AAION) and nonarteritic AION 
(NAION) [1, 2].
We have to differentiate between two different etiologies, and therefore, workout prognosis 
and treatment possibilities are different.
2.1. Nonarteritic ischemic optic neuropathy (NAION)
NAION is the most common cause of sudden optic nerve-related vision loss. It is estimated 
that the incidence of NAION is about 8000/year in the USA and encountered for 90% of the 
optic neuropathies. NAION is mostly unilateral [3] and rare bilaterally. NAION is more 
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frequent in Caucasians, no gender predisposition, and mean age at onset in most studies is 
from 57 to 65 years. No clinically effective treatment exists because little is known about its 
pathophysiology, and there are only few histopathological studies of the acute condition.
NAION [1, 2] typically presents suddenly upon awakening the painless patient notes seeing 
poorly in one eye. Vision in that eye is obscured by a dark shadow, often involving just the 
upper or lower half of vision. On examination, the patient is found with visual acuity reduc-
tion from 20/25 down to hand movement only, relative afferent pupillary defect (RAPD), 
swollen disk (segmental or diffuse) with splinter hemorrhages (see Figure 1), absent of large 
cup, and contralateral disk is small and crowded in 20–40% of the patents [4]. In approxi-
mately 6 months following the infarct visual acuity improves by 3 or more lines of vision on 
the Snellen chart in 42.7% of patients. In addition, vision had worsened by 3 lines or more 
in 12.4% of patients; some clinicians use the term “progressive ischemic optic neuropathy”. 
Second eye involvement occurs in approximately 20% of patients with NAION within 5 years. 
Furthermore, most cases of NAION involve the loss of an altitudinal hemifield (Figure 2) 
(either the upper or mostly lower half of the visual field, but not both), and visual acuity 
remains almost normal or slightly reduced.
Figure 2 shows a few cases of NAION, which involve almost total loss of vision. The mecha-
nism of injury for NAION is used to be controversial. Experts have come to a consensus that 
most cases involve two main risk factors. The first is a predisposition in the form of a type 
of optic disk shape named crowded disk [4, 5] or “disk at risk,” where the cup/disk ratio is 
low (0.0–0.1), and secondly, cardiovascular risk factors as diabetes mellitus, hypertension, 
hypercholesterolemia, and coagulation deficits. Laboratory examinations at the presenta-
tion to differentiate between NAION and AAION include (erythrocyte sedimentation rate 
[ESR] that should be less than 40 mm/h) and C-reactive protein (CRP). It is advised to draw 
complete blood count and serum chemistry especially glucose, serum cholesterol and triglyc-
erides, coagulophatic state, antitrombin III antiphospholipid antibody, and serum fibrino-
gen. Analysis of brain MRI suggests an increasing number of ischemic white matter lesions. 
Figure 1. Disk appearance in nonarteritic ischemic optic neuropathy.
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Additional risk factor such as obstructive sleep apnea, migraine, and hyperhomocysteinemia, 
smoking and optic disk drusen [6]. Ipsilateral carotid disease does not seem to be a risk factor 
for NAION. Association between cerebral and cardiac vascular disease seems to be very cir-
cumstantial. Drugs associated with NAION are amiodarone, phosphodiesterase-5 inhibitors 
such as sildenafil [7], and interferon-a.
Most experts throughout the world believe that there is no accepted treatment to reverse the 
damage. However, a recent large study by Hayreh has shown that if patients are treated with 
large doses of corticosteroid therapy during the early stages of NAION, in eyes with initial visual 
acuity of 20/70 or worse, seen within 2 weeks of onset, there was visual acuity improvement in 
70% in the treated group compared to 41% in the untreated group [8]. Hayreh and Zimmerman 
performed a nonrandomized, open-label trial of systemic corticosteroids for acute NAION, and 
the untreated group had more vascular risk factors than the treated group, and therefore, this 
study was very criticized and not accepted by most neuro-ophthalmologists worldwide.
2.2. NAION treatments attempted with no specific success to improve vision
• Medical [9–11]
• Diphenylhydantoin
• Systemic: aspirin [12], corticosteroids [8]
• Intravitreal: anti-VEGF agents (e.g., Bevacizumab), (see more information) 
• Erythropoietin/erythropoietin receptor agonists
• Surgical: optic nerve sheath fenestration, optic neurotomy (see more information)
• Hyperbaric oxygen [13]
Figure 2. Visual field in NAION and lower altitudinal hemianopia.
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2.2.1. Ischemic optic neuropathy decompression trial (IONDT)
The trial was done to assess the safety and efficacy of optic nerve decompression surgery 
compared with careful follow-up alone in patients with nonarteritic anterior ischemic optic 
neuropathy (NAION). The ischemic optic neuropathy decompression trial (IONDT) is a ran-
domized, single-masked, multicenter trial and was carried out in 1994. Study was done by 244 
patients with NAION and visual acuity of 20/64 or worse.
First group of 125 patients had been randomized to careful follow-up, and second group with 
119 patients had been randomized to surgery, with 6 months of follow-up.
Patients in the surgery group received optic nerve decompression surgery and follow-up 
ophthalmologic examinations; those in the careful follow-up group received ophthalmologic 
examinations at the same times as the surgery group. A parameter of gain and loss of three or 
more lines of visual acuity on the New York Lighthouse chart at 6 months after randomization 
was used by the research group and measured by technicians.
Results showed that patients assigned to surgery did no better when compared with patients 
assigned to careful follow-up regarding improved visual acuity of three or more lines at 
6 months: 32.6% of the surgery group improved compared with 42.7% of the careful follow-
up group. According to the results, IONDT indicates that optic nerve decompression surgery 
for NAION is not effective and may be harmful [14].
2.2.2. Bevacizumab (Avastin®) trial
Intravitreal bevacizumab for the treatment of NAION neuropathy: a prospective trial [15].
2.2.2.1. Methods
In this non-randomized controlled clinical trial, 1.25-mg intravitreal Bevacizumab was com-
pared with natural history [15]. Twenty-five patients were enrolled (17 with treatment and 8 
controls). Patients were examined at baseline, 1, 3, and 6 months with a full neuro-ophthalmic 
exam, automated perimetry, and optic nerve optical coherence tomography (OCT) measure-
ments. The primary outcome measure was change in mean deviation on Humphrey visual 
field testing. Secondary outcome measures were changed in visual acuity and optic nerve 
OCT thickness.
2.2.2.2. Results
(A) There was no significant effect of treatment on the primary outcome measure of mean 
deviation score (P = 0.4). (B) There was no effect of group assignment on the secondary out-
come measures of change in mean Early Treatment Diabetic Retinopathy Study (ETDRS) let-
ters (P = 0.33). (C) No change in nerve fiber layer thickness on OCT (P = 0.11).
Results show optic disc in NAION the results, there was no difference between Bevacizumab 
and natural history for change in visual acuity, visual field, or optic nerve OCT thickness [15].
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2.3. New treatment opportunities (ongoing studies)
NAION is still an enigma regarding pathogenesis and treatment. The current therapeutically 
efforts are to preserve vision and minimize the damage from the primary insult. QPI-1007 is 
a small interfering ribonucleic acid (siRNA) designed to temporarily block cells from mak-
ing Caspase 2 (controls cell apoptosis). Quark pharmaceuticals and NORDIC collaborated 
in a study that uses the possible effect of this drug as a possible neuroprotection therapy for 
NAION.
2.4. Arteritic anterior ischemic optic neuropathy (AAION)
Distinction between AAION and different etiologies of anterior ischemic optic neuropathy. 
will be discussed. AAION is due to temporal arteritis (also called giant cell arteritis (GCA)), 
an inflammatory disease of medium-sized blood vessels that occurs especially with advanc-
ing age (more than 60 years, mostly 70–80 years). Annual incidence rate in population age 
50 years or older is estimated as 15–30/10,000. Female-to-male preponderance of 3.5:1 is preva-
lent in white population of European origin. GCA is associated with polymyalgia rheumatica. 
About 50% of the GCA patients have polymyalgia rheumatica, and 10–20% of the patients with 
polymyalgia rheumatica have GCA. Polymyalgia rheumatica may precede GCA or can occur 
simultaneously.
The symptoms and signs of severe optic neuropathy [16] include the presence of preceding 
transient visual loss, temporal pain, jaw claudications, fatigue, fever, anemia, weight loss, 
and myalgias are strongly suggestive of arteritic ischemic optic neuropathy (AAION). In 
contrast, NAION results from the coincidence of cardiovascular risk factors in a patient with 
“crowded” optic discs. Nonarteritic AION occurs in a slightly younger group and is much 
more common than AAION. Most cases of AAION involve nearly complete vision loss (light 
perception to no light perception), while only a few cases of NAION result in near total loss of 
vision (Figure 3). Swollen disk, elevated CRP, and ESR (60–120 mm/h) are highly suggestive 
of temporal arteritis (arteritic AION) [3, 17]. At times, the optic disk in AAION is characterized 
Figure 3. Shock white disk in arteritic anterior ischemic optic neuropathy.Ó 2018 American Academy of Ophthalmology.
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by a milk-pale edema that may extend to the retina. In some cases, even central retinal occlu-
sion with “cherry -red spot” may occur. Diagnosis is confirmed by temporal biopsy, and if 
the histological result is negative, it is necessary to biopsy the other side. Biopsy is taken from 
several segments along the temporal artery because the inflammation is segmental and may 
be missed by one site biopsy. Another possibility for diagnosis is ultrasound of the temporal 
artery but it is less accurate compared to biopsy.
Neuroimaging is not usually required in patients with typical presentations of giant cell arte-
ritis (GCA) and when performance is generally normal [18]. However, some patients have 
already undergone imaging before neuro-ophthalmic evaluation, and these studies may be 
abnormal. They report four main imaging findings described in the literature:
1. Nonspecific orbital enhancement.
2. Optic nerve parenchymal enhancement.
3. Perineural sheath enhancement.
4. Optic chasmal enhancement.
Other important MRI findings in GCA include those involving the vascular supply not only 
extracranially but also intracranial, particularly vessel wall enhancement of the intramural 
ICA. MRI findings may hold some diagnostic value in distinguishing between A-AION as 
in GCA and in nonarteritic AION, in which they are typically normal. Differential diag-
nosis for these MRI findings can lead to inappropriate testing and delay diagnosis and 
treatment [18].
2.4.1. Summary of AAION
1. GCA is a vascular disorder that may result in devastating visual loss if not treated promptly.
2. Biopsy is the gold standard for diagnosing, and neuroimaging plays a role only in atypical 
presentations.
3. Neuroimaging findings in GCA are often nonspecific and can lead to delay in diagnosis 
and treatment.
Patients are hospitalized for evaluation and intravenous corticosteroid treatment with at least 
1 g/day (3–5 days) of methylprednisolone followed by prednisone 1 g/kg for 10 days and 
then tapering down. The dosage is decreased to 20–40 mg/day in 3 weeks, and treatment is 
continued for 12–18 months. A steroid sparing agent is tocilizumab, a monoclonal human-
ized antibody against interleukin 6 receptor. The dosage is 1 g/day for 12–24 months, and it 
is not given in the first trimester of pregnancy. It can be combined with corticosteroids, and 
this allows decreasing the dosage of the later. During the follow-up period, the inflamma-
tory parameters including sedimentation rate, CPR, platelets, etc. is monitored, and if they 
increase, the dosage is accordingly increased. Treatment is very urgent to avoid AAION in 
the fellow eye, as it can happen even within days or weeks after the first eye was affected. 
Treatment generally does not improve the vision of the affected eye.
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3. Optic neuritis
Optic neuritis is a condition that produces abnormal vision loss without causing ocular abnor-
malities and we have to differentiate between typical and atypical optic neuritis.
1. Typical optic neuritis: Condition of visual loss caused by inflammatory demyelization 
of the optic nerve either idiopathic or associated with multiple sclerosis (MS). The myelin 
sheath is the target of attack.
2. Atypical optic neuritis: The nerve becomes inflamed as a part of uveitis or systemic inflam-
mation treatment can help to improve vision.
3.1. Typical optic neuritis
Optic neuritis is a term used to refer to inflammation of the optic nerve, and it appears in 
two forms: (1) when associated with a swollen optic disk, it is called papillitis or anterior 
optic neuritis. (2) When the optic disk appears normal, the term retro bulbar optic neuritis is 
used. Acute optic neuritis is the most common type of optic neuritis that occurs throughout 
the world and is the most frequent cause of optic nerve dysfunction in young adults mostly 
women. In this chapter, we will provide information about the clinical profile of optic neuritis, 
its natural history, its relationship to multiple sclerosis (MS), and the efficacy of corticosteroid 
treatment according the Optic Neuritis Treatment Trial (ONTT) [19–22].
3.2. Demographics
The annual incidence of acute optic neuritis is estimated in population-based studies to be 
between 1 and 5 per 100,000 people in the general population [23]. The majority of patients 
with acute optic neuritis are aged between 18 and 46 years, with a mean age of 30–35 years. 
However, optic neuritis can occur at any age, and females are affected more commonly than 
males by a ratio of 3:1 to 4:1.
3.3. Clinical presentation
Clinically, there are three major symptoms in patients with acute optic neuritis: (A) central 
visual loss in 90% of the patients. (B) Pain especially is exacerbated by eye movement around 
the affected eye in more than 90% of patients. (C) Relative afferent pupillary defect (RAPD) in 
all patients with unilateral optic neuritis [24].
Loss of central visual acuity occurs within few hours to several days, and the degree of visual 
loss varies from very minimal reduction to counting fingers (in rare cases, complete blindness 
can be observed). The majority of patients describe central vision loss predominately, and 
some of them complain of peripheral field defects. The visual loss is monocular in most cases, 
but particularly in children, both eyes are simultaneously affected.
The presence of pain is a very helpful, differentiating optic neuritis from other causes of optic 
neuropathies such as anterior ischemic optic neuropathy, which produces painless visual loss.
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Examination of a patient with acute optic neuritis reveals evidence of optic nerve dysfunction 
[24]. In addition, color vision (especially red color) is typically impaired in almost all cases 
and is helpful to differentiate from other optic neuropathies.
A relative afferent pupillary defect (RAPD) is demonstrable with the swinging flashlight test 
in all unilateral cases of optic neuritis. Patients with optic neuritis may also have a reduced 
sensation of brightness and contrast sensitivity in the affected eye.
Visual field (VF) scotomas involve many forms of central or peripheral field disturbances 
such as ceco-central scotoma, inferior or superior altitudinal hemianopia, central scotoma, 
Bejerrum scotoma, hemianoptic defects, and more, almost any type of visual field defect (see 
Figure 4).
Presentation of optic disk in the acute phase is mostly normal with sharp disk margins 
and reddish color. Some of the patients with acute optic neuritis have minor degree of disk 
swelling with no correlation to visual acuity or visual field loss [25]. Over approximately 
4–6 weeks, the optic disk in an eye with acute optic neuritis may become or remain normal 
or become pale, and most parameters of vision improve. In the chronic phase, the pallor of 
the optic disk may be diffuse or sectorial from my personal experience often the temporal 
part (42%) because the papillo-macular bundle is damaged in many patients with optic 
neuritis [26].
Figure 4. Visual field possibilities in optic neuritis.
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3.4. Diagnostic studies
Imaging studies in patients with presumed acute optic neuritis are usually performed for 
the following reasons: (A) to rule out particularly a compressive lesion; (B) to determine if a 
cause other than demyelization is responsible for inflammation of the optic nerve; or (C) to 
determine the visual and neurologic prognosis of optic neuritis.
The best imaging study can be done by magnetic resonance imaging (MRI), it can reveal 
demyelization lesions of the optic nerve, manifesting as foci of T2-bright signal, areas of 
enhancement, and even optic nerve enlargement. These lesions are nonspecific, and a similar 
appearance can be observed in patients with infectious and other inflammatory optic neu-
ropathies. The most important application of MRI in patients with optic neuritis is the identi-
fication of signal abnormalities in the white matter of the brain, usually in the periventricular 
region, consistent with demyelization. MRI is the strongest predictor of the eventual develop-
ment of MS in patients with acute isolated optic neuritis. It can show multiple white-matter 
lesions in both cerebral hemispheres, including the periventricular regions.
Cerebrospinal fluid (CSF) analysis in the evaluation of patients with acute optic neuritis is not 
any more a strong predictor for MS. The presence of oligoclonal banding in the CSF is associ-
ated with the development of MS, but it can show false positive results. The powerful predic-
tive value of brain MRI for MS is increased also because the Lumbar puncture examination 
is invasive. Therefore, CSF examination in the evaluation of patients with optic neuritis has 
been reduced. CSF studies in patients with optic neuritis are mostly useful to detect another 
inflammatory or infectious disorder.
3.5. Associated neurologic disorder
3.5.1. Risk factors for developing MS
The presence of at least 1 lesion in the periventricular white matter of the brain MRI is highly 
predictive, family history of MS, white race, old neurologic complains, winter onset, and 
younger age of optic neuritis. Conversely, patients with acute optic neuritis who have a nor-
mal brain MRI, severe disk swelling, a macular star, or disk hemorrhages or older age of onset 
have a low risk of developing MS.
The risk of developing MS [27–29] in a patient who experiences an attack of acute optic neu-
ritis is about 75% in women and 34% in men over the subsequent 15–20 years, with the risk 
being greatest in the first 5 years after the first attack.
3.6. MRI diagnostic criteria for multiple sclerosis
Multiple sclerosis can be diagnosed when the MRI [30–32] in a patient with optic neuritis 
reveals two or more typical lesions of multiple sclerosis, at least one of which is contrast 
enhancing. The demyelization foci in the brain commonly appear in the corpus callosum and 
periventricular white matter and are best seen on T2-flair images.
The number of inactive typical white-matter lesions is the most important criterion for esti-
mating the risk that the patient will develop multiple sclerosis [31]. Optic neuritis with two or 
Causes and Coping with Visual Impairment and Blindness42
more noncontrast enhancing lesions typical of multiple sclerosis on MRI is called a “clinically 
isolated syndrome” and is associated with a high risk of MS. Multiple sclerosis arises in only 
25% of patients in whom MRI reveals no foci of demyelination in the brain. If one or two such 
foci are initially present, the risk is 65%; if three or more are present, it is 78% [31].
3.7. Treatment
Many studies have shown that there are no data to support the efficacy in any treatment to 
alter the final visual outcome during a period of a year after optic neuritis. Treatment with 
corticosteroids is the main treatment option for patients with acute idiopathic optic neuritis. 
The prognosis for visual recovery after acute optic neuritis is very good also without treat-
ment. According the ONTT (IV regimen of corticosteroids) [19–21, 32], steroid treatment 
should be delivered in acute optic neuritis if symptoms of 8 days duration or less. Begin 
with 3 days of intravenous Methylprednisolone in a dose of 1 g/day followed by 11 days 
course of oral prednisone at a dose of 1 mg/kg/day with a taper over 3 days. The ONTT was 
done in randomizing 457 patients with acute optic neuritis, comparing a group of patients 
following the IV steroid regimen versus a group of patients receiving placebo. The results of 
the trial showed that this regimen does not affect the final visual outcome of a patient, but it 
accelerates the recovery of vision compared with no treatment in the first 2 years. In addition, 
patients who experience an attack of acute optic neuritis should not be treated with low-dose 
oral prednisone alone because it provide no effect of visual outcome and may double the 
recurrence rate for optic neuritis.
The ONTT [19] results had another important aspect of treatment for acute optic neuritis 
regarding the possibility of having impact on the development of MS. Patients who were 
treated with the intravenous followed by oral corticosteroid regimen had a reduced rate of 
developing clinically definite MS during the first 2 years following treatment. MS developed 
in only 8% of patients who were treated according the corticosteroid regimen versus 17% of 
patients in the placebo group. This benefit of treatment was seen only in patients who had 
abnormal brain MRI at the time of onset of the optic neuritis. The protective effect was short 
and by 3 years after optic neuritis groups treated with ONTT IV regimen versus placebo 
groups had equal incidence to develop MS. These findings suggest that a patient with acute 
optic neuritis who has an abnormal brain MRI may benefit in the short term (2 years) from 
treatment with the IV/oral steroid regimen.
A number of agents other than or in addition to systemic corticosteroids have been found 
to reduce the risk of the development of MS following an attack of acute optic neuritis over 
a longer period of time than corticosteroids alone. The Controlled High-Risk Avonex MS 
[33] Prevention Study (CHAMPS), a randomized, double-blind, placebo-controlled trial that 
enrolled patients with a first demyelinating event, offer some help. Weekly intramuscular 
injection with 30 ug of beta interferon 1a (Avonex) to patients who had 2 or more white-matter 
lesions of at least 3 mm on a brain MRI together with a 14-day course of Methylprednisolone 
followed by prednisone lowered the probability for MS. The group of patients receiving inter-
feron beta-1a had a 44% reduction in the 3-year risk of developing MS compared with those 
receiving placebo. In addition, patients in the interferon group had fewer new and enhancing 
brain MRI lesions.
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To conclude, a clinician should discuss with a patient having acute optic neuritis the treat-
ment benefits comparing to no treatment emphasizing that there is a good chance (more than 
80%) that visual acuity will recover to 20/20 within a year without treatment. It is important to 
explain the patient the relation between optic neuritis and the chances of developing MS. No 
treatment affects the final outcome of visual acuity.
3.8. Visual prognosis
The natural history of acute idiopathic optic neuritis is to worsen over several days to 2 weeks 
and then to improve mostly rapidly. Improvement can continue to occur up to 1 year after 
the onset of visual symptoms. I had some patients of which improvement started only after 2 
months but it is uncommon. The mean visual acuity 1 year after an attack of otherwise uncom-
plicated optic neuritis is 20/20, and less than 10% of patients have permanent visual acuity less 
than 20/40. Most parameters of visual function, including contrast sensitivity, color perception, 
and visual field, improve in conjunction with improvement in visual acuity. According to some 
investigators, most patients retain excellent vision for at least 15 years after their first attack [24].
Although the overall prognosis for visual acuity after an attack of acute optic neuritis 
is extremely good, some patients have persistent severe visual loss after a single episode. 
Furthermore, even patients with improvement in visual function to “normal” may complain 
of movement-induced photopias or transient loss of vision with overheating or exercise 
(Uhthoff symptom). The ONTT since 1992 has made it clear that the risk of a recurrence or 
a new attack is substantially higher in patients treated with low-dose oral prednisone as 
opposed to patients who receive no treatment or who are treated according the ONTT [19]. 
About 25% of patients who experience an attack of acute optic neuritis will experience a sec-
ond attack in that eye or a new attack in the previously unaffected eye.
3.9. Atypical optic neuritis
Optic neuritis that develops before the age of 15 years or after the age of 50 years may be 
atypical. Many of these cases have no periocular pain, and visual decline is over few weeks. 
Atypical optic neuritis should be divided to three categories: infectious, immune, and Sarcoid. 
Most of them appear with disk edema.
3.10. Infectious optic neuritis
This may occur in meningitis/encephalitis [34] and is treatable. The pathogens could be bac-
teria (Homophiles, Streptococcus, Staphylococcus, spirochetes, or mycobacteria), protozoa as 
Toxoplasmosis, fungi as Cryptococcus or Aspergillus, or herpes viruses [35, 36]. Syphilitic 
optic neuritis can develop very rapidly from every stage of the disease. Tuberculosis causes 
meningitis. Lyme optic neuritis is rare and mostly associated with those who visited near 
New Haven, Conn, USA.
Another type of optic neuritis is called Leber’s stellate neuro retinitis caused by Bartonella hense-
lae responsible for cat-scratch disease. States with disk edema and within weeks, we can find 
star shape collection of hard micro-exudates (star-shape) at the macula called neuroretinitis [37].
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3.11. Immune optic neuritis
Optic neuritis can appear within days or weeks after systemic influenza illness [34] or vac-
cination [38]; often binocular with good vision recovery [32]. Atypical optic neuritis is also 
associated with acute disseminated encephalomyelitis (ADEM), a condition in which mul-
tiple CNS manifestations occur at once; in most cases, patients recover and never recur. Some 
authors recommend high dose of corticosteroid treatment.
In optic neuritis, if an underling cause is found, it should be treated with either corticosteroid 
or immunosuppressive medications.
Optic neuritis is rare in Guillain-Barre syndrome, Crohn’s disease, ulcerative colitis, behest’s 
disease, Wegener’s granulomatosis, and lupus erythematosus.
3.12. Sarcoidosis
When the optic nerve is involved, the vision declines and the optic disk might be swollen, 
with or without systemic signs. Vision recovers with corticosteroid therapy. Relapses are 
common [39].
• Recommended laboratory tests mostly for atypical cases
 ○ C-reactive protein
 ○ Complete blood count
 ○ Serum chemistry
 ○ Blood sugar
 ○ Vitamin B
12
 ○ Rheumatoid factor
 ○ Antinuclear antibodies
 ○ Anti-phospholipids antibodies
 ○ Anti-ds-DNA antibodies
 ○ Lupus anticoagulant
 ○ Serum angiotensin-converting enzyme test
 ○ Borrelia serology
 ○ Urinalysis
• Additional tests in case of “clinically possible differential diagnosis”
 ○ Anti-neutrophilic cytoplasmic antibodies (ANCA)
 ○ Extractable nuclear antibody (ENA) profile
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 ○ Auto antibodies against aquaporin-4
 ○ HIV serology
 ○ Human T-lymphotropic virus type 1 (HTLV-1) serology
 ○ Treponema pallidum hemagglutination assay (TPHA), long-chained fatty acids
 ○ Mycoplasma serology
 ○ Urinary methylmalonate excretion
4. Anterior versus posterior traumatic optic neuropathy
Traumatic optic neuropathy is the name given to the syndrome of an optic neuropathy after 
head or ocular trauma in the absence of other causes [40]. Like any other optic neuropathy, 
there are variable degrees of visual acuity and visual field loss and an afferent pupillary defect 
if unilateral or significantly asymmetric.
Traumatic optic neuropathy is either anterior or posterior and within each category can either 
be direct or indirect. Trauma to the anterior optic nerve usually injures the central retinal artery 
and vein, which enter or exit the nerve approximately 10 mm posterior to the globe. This vas-
cular injury often results in retinal infarct. Hemorrhages are usually the result of severing the 
pial vessels with or without disk edema and rarely manifestations of central retinal or branch 
artery occlusion, central retinal vein occlusion, or anterior ischemic optic neuropathy. Axonal 
injury in the posterior optic nerve does not cause any acute effects on the disk, nerve fiber 
layer, or retinal ganglion cell layers. Axonal transport abnormalities posteriorly do not affect 
the more anterior nerve fibers, and so disk edema is not seen in posterior traumatic optic neu-
ropathy. For these reasons, isolated posterior traumatic optic neuropathy is associated with a 
normal fundus examination at presentation. Only after a few weeks, we can see the structural 
signs of optic neuropathy evident, namely disk pallor and thinning of the retinal nerve fiber 
layer. A particular type of posterior traumatic optic neuropathy is when there is injury to 
the chiasm, in which case, there may be unilateral or bilateral temporal visual field defects 
respecting the vertical meridian. Rare chiasmal injury can be seen with posterior avulsion of 
the optic nerve, for example, traumatic enucleation, or penetration from a foreign body.
4.1. Direct anterior traumatic optic neuropathy
Direct anterior traumatic optic neuropathy is defined when there is penetration of the optic 
nerve by a foreign body or projectile. Anterior direct optic nerve injuries result from medial 
penetrating orbital trauma that damages the anterior optic nerve, for example, a knife tran-
secting the optic nerve just posterior to the globe. This is because the optic nerve course 
transverses the medical part of the deep orbit and is not protected there by the bones or the 
eye. Posterior direct optic nerve injuries result from penetrating orbital or head trauma more 
posteriorly, for example, a bullet that passes just anterior to the chiasm. Direct injuries tend 
to produce severe and immediate visual loss, with little likelihood of recovery. The reason 
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for this presumably is that a major element in these injuries is transection injury to retinal 
ganglion cell axons, which causes instantaneous loss of axonal conduction and an inability to 
regenerate axons later.
4.2. Indirect anterior traumatic optic neuropathy
This is diagnosed when traumatic optic neuropathy occurs without a history of foreign body. 
It occurs in anterior indirect injuries, which associated with sudden rotation of the globe from 
blunt trauma. Examples include a digit trauma to the globe or falling and hitting the eye on 
the corner of a table. Anterior indirect traumatic optic neuropathy can cause partial or total 
avulsion of the optic nerve, with associated peripapillary hemorrhage.
4.3. Posterior indirect traumatic optic neuropathy
Posterior indirect injury is the most common cause of traumatic optic neuropathy. It results 
from blunt head trauma that transmits a concussive force to the optic nerve, resulting in con-
tusion at the optic canal. There may be little or no evidence of significant head trauma; a fall 
from a bicycle may suffice. In other cases, there is multisystem trauma or significant brain 
injury. Loss of consciousness occurs in 40–72% of patients with traumatic optic neuropathy. 
Motor vehicle and bicycle accidents are the most frequent causes of traumatic optic neuropa-
thy, accounting for 17–63% of cases. Traumatic optic neuropathy may be iatrogenic, especially 
after maxillofacial or endoscopic surgery as a result of inadvertent direct injury to the optic 
nerve or transmitted force fracturing the optic canal. The common site of posterior indirect 
optic nerve injury is at the optic canal; the intracranial optic nerve is the next most common 
site of injury. There may or may not be bone fractures. Despite being most common, poste-
rior indirect traumatic optic neuropathies fortunately occasionally have the most favorable 
prognosis, its spontaneous visual recovery sometimes occurring at variable times after injury. 
Presumably, the injury causes concussion and focal blockade of axonal conduction without 
loss of its structural integrity. Once there is healing of the edema or other molecular events 
blocking conduction, axonal function can return. The severity of initial visual loss in patients 
with traumatic optic neuropathy varies from no light perception to 20/20, with sometimes 
only a visual field defect as functional evidence of disease. An afferent pupillary defect is 
always present and is the major clue for the diagnosis in the presence of otherwise normal 
eye. Patients with very poor vision (e.g., light perception only or no light perception) are less 
likely to improve, regardless of therapy, than patients with vision better than light perception. 
The reason is likely that severe injury causes axonal transection, membrane disruption, or 
cytoskeletal disorganization, any of which can lead to axonal dissolution and irreversible loss 
of conduction of visual information. In some cases, the visual loss only begins several hours 
to days after the injury. If this happens, the possibility of an intrasheath hemorrhage should 
be entertained, and neuroimaging should be repeated.
4.4. Neuroimaging
The diagnosis is radiological. It is essential in the evaluation of a patient with traumatic optic neu-
ropathy not only for demonstrating correlative signs of injury but also detection of pre-existing 
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structural lesions and coincident intracranial effects of trauma, e.g., hematomas or carotid cav-
ernous fistulas. CT scanning is superior to magnetic resonance imaging (MRI) in delineating 
fractures of bone. It is critical that CT be performed with very thin sections that are aimed to 
the optic canal, and reconstructions performed, particularly in the coronal plane. About 20 to 
50% of patients with posterior traumatic optic neuropathy have evidence of an optic canal frac-
ture by neuroimaging, and sometimes, the clue is a small loss of contour of bone. Although the 
displacement on neuroimaging may be small, it is possible that at the time of injury, there was 
a much larger displacement of the bone into the canal. Even in the absence of a fracture, blood 
in the sphenoid sinus should raise suspicion for optic nerve injury. MRI is better for imaging 
soft tissue, particularly the intracranial optic nerve and chiasm, and may be useful for delineat-
ing intrasheath hemorrhage that occurs at the orbital portion from penetrating injury (anterior 
direct TON). It is critical that MRI only be performed after a metallic intracranial, intraorbital, or 
intraocular foreign body has been ruled out by CT scanning or conventional radiography. If CT 
is used for screening, care should be taken to use thin slices and no interslice skip.
4.5. Treatment of traumatic optic neuropathy
In anterior and direct traumatic optic neuropathy, there is no evidence that treatment of ante-
rior optic injuries or direct optic nerve injuries is efficacious. In the former, the concurrent 
vascular injuries cause direct ischemia and infarction to the neural retina and/or optic nerve 
head, and the time until irreversible neuronal death is measured in minutes to hours. In the 
latter, there is often sufficient direct axonal trauma to disrupt the integrity of the axon, up 
to and including its transection, and in the central nervous system of mammals, this is a 
point of no return for neuronal function. An exception is anterior traumatic optic neuropathy 
associated with neuroimaging evidence of an enlarged optic nerve sheath. In these cases, an 
optic nerve sheath fenestration should be performed in the hopes of evacuating an intrasheath 
hematoma.
4.6. Treatment of posterior indirect traumatic optic neuropathy
With respect to posterior indirect traumatic optic neuropathy, the three commonly used 
approaches that have been used are very high doses (“mega doses”) of corticosteroids [41], 
decompression of the optic canal, and observation alone; there is insufficient evidence from 
good quality randomized trials to guide decision-making on how to treat traumatic optic 
neuropathy. Because visual function often spontaneously improves in this disease, clinical 
trials are particularly necessary for physicians to select therapies based on evidence. Mega-
dose corticosteroids experimental models of white matter trauma in animals showed that 
doses of 15–30 milligrams per kilogram of intravenous methylprednisolone are protective for 
injured neurons [41]. The NASCIS 2 and 3 studies found that patients treated within 8 hours 
of spinal cord injury with a loading dose of 30 milligrams per kilogram of intravenous meth-
ylprednisolone load followed by 5.4 ml/kg/hr continuous infusion for 48 hours had a better 
outcome than control patients [42, 43]. Extrapolating these results to traumatic optic nerve 
injury, it was thought reasonable to believe that similar doses should be used for injury to this 
comparable central nervous system white matter structure. However, over the years, there 
has been controversy about interpretation of the NASCIS data [44, 45], and its application 
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to the treatment of spinal cord injury is not uniform [46, 47]. Furthermore, animal and cell 
culture data suggest that high doses of methylprednisolone may actually be toxic for the 
retinal ganglion cell and/or its axon [48–50]. Finally, the Corticosteroid Randomization After 
Significant Head Injury (CRASH) trial demonstrated that 48 hours of mega-dose methylpred-
nisolone significantly increased the risk of death after head injury [51], with a hazard ratio at 
6 months of 1.15 (95% CI 1.07–1.24) [52].
The authors concluded that “These final results still provide clear evidence that treatment 
with corticosteroids following head injury affords no material benefit.”
4.7. Optic canal decompression
Decompression of the optic canal is usually achieved through the transethmoidal route, most 
commonly via an external ethmoidectomy or endonasally [53]. The canal is then decom-
pressed inferomedially from the superior lateral wall of the sphenoid sinus, with care taken to 
avoid the carotid artery. Although the canal can also be decompressed through an intracranial 
approach, the former is less invasive. However, if surgery in the area is being performed for 
other reasons necessitating unroofing of the canal, then an argument can be made that decom-
pression of the canal should be done through this approach. However, there is also no evi-
dence that optic canal decompression is efficacious. A recent Cochrane review concluded that 
there is no conclusive evidence that any particular form of surgical decompression improves 
the visual outcome in TON. The decision to proceed with surgery in TON remains controver-
sial and each case needs to be assessed on its own merits. The final decision will inevitably 
reflect a combination of clinical judgment, the availability of local surgical expertise, and the 
patient’s perception of the possible risks and benefits. If surgery is to be considered, it should 
only be performed in centers with experience with the procedure. Because of the possibility 
that the carotid may be iatrogenic injured, there should be informed consent regarding the 
risk of death or stroke. Surgery should not be performed on an unconscious patient because 
of the difficulty in assessing visual function. Observation of traumatic optic neuropathy may 
improve without any treatment. There are no convincing randomized control trials to show 
a treatment benefit in traumatic optic neuropathy, and a nonrandomized concurrent com-
parative study did not demonstrate clear differences between treatments and observation. 
Therefore, when a patient cannot give informed consent for corticosteroid or surgical therapy, 
some neuro-ophthalmologists may simply observe the patient as none of these treatments 
have been proved to be superior.
Author details
Eitan Z. Rath1,2*
*Address all correspondence to: erath@netvision.net.il
1 Department of Ophthalmology, Galilee Medical Center, Nahariya, Israel
2 Faculty of Medicine, Bar-Ilan University, Safad, Israel
Visual Loss in Neuro-Ophthalmology
http://dx.doi.org/10.5772/intechopen.80682
49
References
[1] Arnold AC. Ischemic optic neuropathies. Ophthalmology Clinics of North America. 
2001;14:83-98
[2] Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ, Biousse V, et al., 
editors. Clinical Neuro-Ophthalmology. 6th ed. Vol. Vol. 1. Philadelphia: Lippincott, 
Williams & Wilkins; 2005. pp. 349-384
[3] Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic 
neuropathy: Population-based study in the state of Missouri and Los Angeles County, 
California. Journal of Neuro-Ophthalmology. 1994;14:38-44
[4] Beck RW, Servais GE, Hayreh SS. Anterior ischemic optic neuropathy. IX. Cup-to-disc 
ratio and its role in pathogenesis. Ophthalmology. 1987;94:1503-1508 The Journal of the 
American Medical Association. 1995;273:625-32
[5] Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. Journal of 
Neuro-Ophthalmology. 2003;23:157-163
[6] Purvin V, King R, Kawasaki A, et al. Anterior ischemic optic neuropathy in eyes with 
optic disc drusen. Archives of Ophthalmology. 2004;122:48-53
[7] Hayreh SS. Amiodarone, erectile dysfunction drugs, and non-arteritic ischemic optic 
neuropathy. Journal of Neuro-Ophthalmology. 2006;26:154-155
[8] Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: Role 
of systemic corticosteroid therapy. Graefe's Archive for Clinical and Experimental 
Ophthalmology. 2008;246:1029
[9] Miller NR, Arnold AC. Current concepts in the diagnosis, pathogenesis and manage-
ment of nonarteritic anterior ischaemic optic neuropathy. Eye. 2015;29:65-79
[10] Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of nonarteritic anterior ischemic 
optic neuropathy. Survey of Ophthalmology. 2010;55:47-63
[11] Arnold AC, Levin LA. Treatment of ischemic optic neuropathy. Seminars in Ophthal-
mology. 2002;17:39-46
[12] Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in nonarteritic anterior isch-
emic optic neuropathy. American Journal of Ophthalmology. 1997;123:212-217
[13] Arnold AC, Hepler RS, Lieber M, et al. Hyperbaric oxygen therapy for nonarteritic ante-
rior ischemic optic neuropathy. American Journal of Ophthalmology. 1996;122:535-541
[14] The Ischemic Optic Neuropathy Decompression Trial Research Group, Ischemic Optic 
Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery 
for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be 
harmful. Journal of the American Medical Association. 1995;273:625-632
Causes and Coping with Visual Impairment and Blindness50
[15] Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of non-
arteritic anterior ischemic optic neuropathy: A prospective trial. Eye (London, England). 
2013;27:538-544
[16] Hayreh SS, Podhajsky PA, Zimmerman P. Ocular manifestations of giant cell arteritis. 
American Journal of Ophthalmology. 1998;125:509-520
[17] Weyand CM, Goronzy JJ. Giant Cell Arteritis. The New England Journal of Medicine. 
2014;371:50-57
[18] D'Souza NM, Morgan ML, Almarzouqi SJ, Lee AG. Magnetic resonance imaging find-
ings in giant cell arteritis. Eye (London, England). 2016;30:758-762
[19] Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticoste-
roids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. The New 
England Journal of Medicine. 1992;326:581-588
[20] Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis 
on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. 
The New England Journal of Medicine. 1993;329:1764-1769
[21] Beck RW, Cleary PA. Optic Neuritis Study G. Optic neuritis treatment trial: One-year 
follow-up results. Archives of Ophthalmology. 1993;111:773-775
[22] Vedula SS, Brodney-Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. 
Cochrane Database of Systematic Reviews. 24 Jan 2007;(1):CD001430 
[23] Stunkel L, Kung NH, Wilson B, McClelland CM, Van Stavern GP. Incidence and causes 
of over diagnosis of optic neuritis. JAMA Ophthalmology. 2018;136:76-81
[24] Shams PN, Plant GT. Optic neuritis: A review. International MS Journal. 2009;16:82-89
[25] Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neu-
ritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. 
Archives of Ophthalmology. 1993;111:231-234
[26] Rath EZ, Rehany U, Linn S, Rumelt S. Correlation between optic disc atrophy and aetiol-
ogy: Anterior ischaemic optic neuropathy vs optic neuritis. Eye. 2003;17(9):1019-1024
[27] Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neu-
ritis treatment trial follow-up. Archives of Neurology. 2008;65:727-732
[28] Marques IB, Matias F, Silva ED, Cunha L, Sousa L. Risk of multiple sclerosis after optic 
neuritis in patients with normal baseline brain MRI. Journal of Clinical Neuroscience. 
2013;21:583-586
[29] Horwitz H, Friis T, Modvig S, et al. Differential diagnoses to MS: Experiences from an 
optic neuritis clinic. Journal of Neurology. 2014;261:98-105
[30] Montalban X, Tintoré M, Swanton J, Barkhof F, Fazekas F, Filippi M, Frederiksen J, 
Kappos L, Palace J, Polman C, Rovaris M, de Stefano N, Thompson A, Yousry T, Rovira A, 
Visual Loss in Neuro-Ophthalmology
http://dx.doi.org/10.5772/intechopen.80682
51
Miller DH. MRI criteria for MS in patients with clinically isolated syndromes. Neurology. 
2010;74:427-434
[31] Soelberg K, Skejoe HPB, Grauslund J, Smith TJ, Lillevang ST, Jarius S, Wildemann B, 
Paul F, Asgari N. Magnetic resonance imaging findings at the first episode of acute optic 
neuritis. Multiple Sclerosis and Related Disorders. 2018;20:30-36
[32] Wilhelm H, Schabet M. The diagnosis and treatment of optic neuritis. Deutsches 
Ärzteblatt International. 2015;112:616-625
[33] Boghen D, CHAMPS Study Group. Interferon β-1a for optic neuritis patients at high risk 
for multiple sclerosis. Journal of Neuro-Oncology. 2002;22:247-248
[34] Vianello FA, Osnaghi S, Laicini EA, Milani GP, Tardini G, Cappellari AM, Lunghi G, 
Agostoni CV, Fossali EF. A typical Optic neuritis associated with influenza B virus 
meningoencephalitis. Journal of Clinical Virology. 2014;61:463-465
[35] De Seze J. Inflammatory optic neuritis: From multiple sclerosis to neuromyelitis optica. 
Neuroophthalmology. 2013;37:141-145
[36] Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: A systematic 
review of 122 cases reported. Journal of Neurology. 2013;261:17-26
[37] Purvin V, Sundaram S, Kawasaki A. Neuroretinitis: Review of the literature and new 
observations. Journal of Neuro-Ophthalmology. 2011;31:58-68
[38] Moradian S, Ahmadieh H. Early onset optic neuritis following measles-rubella vaccina-
tion. Journal of Ophthalmic and Vision Research. 2008;3:118-122
[39] Kidd DP, Burton BJ, Graham EM, Plant GT. Optic neuropathy associated with systemic 
sarcoidosis. Neurology: Neuroimmunology and Neuroinflammation. 2016;3:e270
[40] Mauriello JA, DeLuca J, Krieger A, et al. Management of traumatic optic neuropathy—A 
study of 23 patients. The British Journal of Ophthalmology. 1992;76:349
[41] Hall ED. The neuroprotective pharmacology of methylprednisolone. Journal of Neuro-
surgery. 1992;76:13
[42] Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methyl-
prednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the 
Second National acute spinal cord injury study. The New England Journal of Medicine. 
1990;322:1405
[43] Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 
24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord 
injury. Results of the Third National acute spinal cord injury randomized controlled 
trial. National acute spinal cord injury study. JAMA. 1997;277:1597
[44] Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the 
National acute spinal cord injury studies (II and III) of methylprednisolone in acute spi-
nal cord injury. Journal of Spinal Disorders. 2000;13:185
Causes and Coping with Visual Impairment and Blindness52
[45] Levin LA, Baker RS. Management of traumatic optic neuropathy. Journal of Neuro-
Ophthalmology. 2003;23:72
[46] Hurlbert RJ, Moulton R. Why do you prescribe? Methylprednisolone for acute spinal 
cord injury? A Canadian perspective and a position statement. The Canadian Journal of 
Neurological Sciences. 2002;29:236
[47] Molloy S, Price M, Casey AT. Questionnaire survey of the views of the delegates at the 
European cervical spine research society meeting on the administration of methylpred-
nisolone for acute traumatic spinal cord injury. Spine. 2001;26:E562
[48] Ohlsson M, Westerlund U, Langmoen IA, et al. Methylprednisolone treatment does not 
influence axonal regeneration or degeneration following optic nerve injury in the adult 
rat. Journal of Neuro-Ophthalmology. 2004;2411
[49] Diem R, Hobom M, Maier K, et al. Methylprednisolone increases neuronal apoptosis 
during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective 
pathway. The Journal of Neuroscience. 2003;23:6993
[50] Steinsapir KD, Goldberg RA, Sinha S, et al. Methylprednisolone exacerbates axonal 
loss following optic nerve trauma in rats. Restorative Neurology and Neuroscience. 
2000;17:157
[51] Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death 
within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial: 
Randomized placebo-controlled trial). Lancet. 2004;364:1321
[52] Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised pla-
cebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes 
at 6 months. Lancet. 2005;365:195
[53] Levin LA, Joseph MP, Rizzo JF 3rd, et al. Optic canal decompression in indirect optic 
nerve trauma. Ophthalmology. 1994;101:566
Visual Loss in Neuro-Ophthalmology
http://dx.doi.org/10.5772/intechopen.80682
53

